PMID- 36227963
OWN - NLM
STAT- MEDLINE
DCOM- 20221017
LR  - 20221019
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 10
DP  - 2022
TI  - NSAIDs affect dendritic cell cytokine production.
PG  - e0275906
LID - 10.1371/journal.pone.0275906 [doi]
LID - e0275906
AB  - BACKGROUND: Immunotherapy is now considered as the new pillar in treatment of 
      cancer patients. Dendritic cells (DCs) play an essential role in stimulating 
      anti-tumor immune responses, as they are capable of cross-presenting exogenous 
      tumor antigens in MHCI complexes to activate naive CD8+ T cells. Analgesics, like 
      non-steroid anti-inflammatory drugs (NSAIDs), are frequently given to cancer 
      patients to help relieve pain, however little is known about their impact on DC 
      function. METHODS: Here, we investigated the effect of the NSAIDs diclofenac, 
      ibuprofen and celecoxib on the three key processes of DCs required for proper 
      CD8+ cytotoxic T cell induction: antigen cross-presentation, co-stimulatory 
      marker expression, and cytokine production. RESULTS: Our results show that 
      TLR-induced pro- and anti-inflammatory cytokine excretion by human monocyte 
      derived and murine bone-marrow derived DCs is diminished after NSAID exposure. 
      CONCLUSIONS: These results indicate that various NSAIDs can affect DC function 
      and warrant further investigation into the impact of NSAIDs on DC priming of T 
      cells and cancer immunotherapy efficacy.
FAU - Raaijmakers, Tonke K
AU  - Raaijmakers TK
AUID- ORCID: 0000-0001-6408-4061
AD  - Department of Radiation Oncology, Radiotherapy & OncoImmunology Laboratory, 
      Radboud Institute for Molecular Life Sciences, Radboud UMC, Nijmegen, The 
      Netherlands.
AD  - Department of Anesthesiology, Pain and Palliative Medicine, Radboud UMC, 
      Nijmegen, The Netherlands.
FAU - van den Bijgaart, Renske J E
AU  - van den Bijgaart RJE
AD  - Department of Radiation Oncology, Radiotherapy & OncoImmunology Laboratory, 
      Radboud Institute for Molecular Life Sciences, Radboud UMC, Nijmegen, The 
      Netherlands.
FAU - Scheffer, Gert Jan
AU  - Scheffer GJ
AD  - Department of Anesthesiology, Pain and Palliative Medicine, Radboud UMC, 
      Nijmegen, The Netherlands.
FAU - Ansems, Marleen
AU  - Ansems M
AD  - Department of Radiation Oncology, Radiotherapy & OncoImmunology Laboratory, 
      Radboud Institute for Molecular Life Sciences, Radboud UMC, Nijmegen, The 
      Netherlands.
FAU - Adema, Gosse J
AU  - Adema GJ
AUID- ORCID: 0000-0002-6750-1665
AD  - Department of Radiation Oncology, Radiotherapy & OncoImmunology Laboratory, 
      Radboud Institute for Molecular Life Sciences, Radboud UMC, Nijmegen, The 
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20221013
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cytokines)
RN  - 144O8QL0L1 (Diclofenac)
RN  - JCX84Q7J1L (Celecoxib)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/metabolism/pharmacology
MH  - Antigens, Neoplasm/metabolism
MH  - CD8-Positive T-Lymphocytes
MH  - Celecoxib/metabolism/pharmacology
MH  - Cytokines/metabolism
MH  - *Dendritic Cells
MH  - Diclofenac/metabolism
MH  - Humans
MH  - Ibuprofen/metabolism
MH  - Mice
MH  - *Neoplasms/therapy
PMC - PMC9560552
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/10/14 06:00
MHDA- 2022/10/18 06:00
PMCR- 2022/10/13
CRDT- 2022/10/13 14:04
PHST- 2022/04/24 00:00 [received]
PHST- 2022/09/26 00:00 [accepted]
PHST- 2022/10/13 14:04 [entrez]
PHST- 2022/10/14 06:00 [pubmed]
PHST- 2022/10/18 06:00 [medline]
PHST- 2022/10/13 00:00 [pmc-release]
AID - PONE-D-22-12054 [pii]
AID - 10.1371/journal.pone.0275906 [doi]
PST - epublish
SO  - PLoS One. 2022 Oct 13;17(10):e0275906. doi: 10.1371/journal.pone.0275906. 
      eCollection 2022.